BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
— Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet
— Graft vascularization was achieved by embedding vascular pedicle into the scaffold
— Recently published as a case report in the Journal of Personalized Medicine
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that a team at the Hannover Medical School, Clinic for Trauma Surgery, led by Prof. Dr. med. Philipp Mommsen, successfully used a customized, resorbable bone replacement scaffold produced by BellaSeno to reconstruct a 14 cm segmental bone defect of the radial shaft after third degree open infected fracture due to traumatic gunshot injury.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
– Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited review is designated to investigational drugs that treat a serious or life-threatening condition and fill an unmet medical need.
– First dose level rated as safe by independent Data Safety Monitoring Board
– Second dose level to be administered according to plan
– THE001 designed as targeted tumor treatment independent of specific molecular targets or tumor subtypes
Thermosome, a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001. The first dose level was safe and well tolerated as assessed by the DSMB.